KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Share-based Compensation (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Share-based Compensation for 14 consecutive years, with $15.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 3.05% to $15.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $63.4 million, a 0.16% change, with the full-year FY2025 number at $58.0 million, down 6.9% from a year prior.
  • Share-based Compensation was $15.9 million for Q4 2025 at Bio-Rad Laboratories, up from $14.9 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $16.4 million in Q4 2024 to a low of $11.7 million in Q1 2021.
  • A 4-year average of $15.1 million and a median of $15.9 million in 2023 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: increased 21.95% in 2021, then decreased 3.05% in 2025.
  • Bio-Rad Laboratories' Share-based Compensation stood at $15.0 million in 2021, then increased by 8.0% to $16.2 million in 2023, then grew by 1.23% to $16.4 million in 2024, then dropped by 3.05% to $15.9 million in 2025.
  • Per Business Quant, the three most recent readings for BIO's Share-based Compensation are $15.9 million (Q4 2025), $14.9 million (Q3 2025), and $16.4 million (Q4 2024).